Form 4: Nautilus Biotechnology's Chief Marketing Officer Acquires Stock Options

Kentaro Suzuki, Chief Marketing Officer of Nautilus Biotechnology, acquired stock options for 50,000 shares of common stock on March 3, 2025, according to a recent SEC filing.

Summary

• Kentaro Suzuki, the Chief Marketing Officer of Nautilus Biotechnology, Inc., filed a Form 4 with the SEC on March 4, 2025.
• The filing reports a transaction that occurred on March 3, 2025, where Suzuki acquired options to purchase 50,000 shares of Nautilus Biotechnology's common stock at an exercise price of $1.24.
• These options vest over a period of 48 months, with 25% vesting on the first anniversary of January 1, 2025, and the remainder vesting monthly thereafter.
• Suzuki also has a power of attorney agreement in place, authorizing several individuals to act on his behalf in matters related to SEC filings.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The sentiment is slightly positive as it indicates an executive's increased stake in the company, but it's a routine filing.

Positives

• The acquisition of stock options by a key executive could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance beyond the vesting schedule of the options.

Industry Context

This type of SEC filing is standard for reporting changes in beneficial ownership by company insiders. It's common for executives to receive stock options as part of their compensation packages, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a common component of executive compensation packages in the biotechnology industry.
• Vesting schedules, like the 48-month period described, are typical to incentivize long-term commitment.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options as part of their executive compensation plans.

Stakeholder Impact

• The granting of stock options to a key executive can potentially align the executive's interests with those of the shareholders.

Key Dates